EE355 The Impact of Dynamic Mortality on the Cost-Effectiveness of Axicabtagene Ciloleucel Versus Standard of Care As Second-Line Therapy in Patients With Large B-Cell Lymphoma in France
Abstract
Authors
A Zang L Chambry S Leproust B Doble S Vadgama